Advanced Malignant Tumors
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Advanced Malignant Tumors is an early-stage landscape with 4 programs across 25 companies. The most active players are Bristol-Myers Squibb, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Karuna Therapeutics, Inc., a Bristol Myers Squibb company.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Bristol-Myers Squibb
2 programs
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Imclone
1 program
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
0 programs
SUNHO（China）BioPharmaceutical CO., Ltd.
0 programs
Pipeline
Programs by Phase
Analysis
Modality Breakdown
60%
Small molecule
3 of 5 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 5 classified programs, each share of the total. Modality classified for 100% of 5 pipeline programs.
Analysis
Trial Status
85
clinical trials
Clinical Trials
Trial Activity
85 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)